-
公开(公告)号：US11833248B2
公开(公告)日：2023-12-05
申请号：US16570723
申请日：2019-09-13
申请人： Novo Nordisk A/S
IPC分类号： A61K38/26 , A61P7/12 , C07K14/605 , A61K38/00 , A61P3/04 , A61K38/28 , C07K5/00 , C07K7/00 , C07K16/00 , C07K17/00 , A61K9/20 , A61P3/10
CPC分类号： A61K9/2013 , A61K38/26 , A61P3/04 , A61P3/10 , C07K14/605
摘要： The invention relates to pharmaceutical compositions comprising a peptide, such as a GLP-1 peptide and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.
-
公开(公告)号：US20220265777A1
公开(公告)日：2022-08-25
申请号：US17628459
申请日：2020-08-06
申请人： Novo Nordisk A/S
发明人： Betty Lomstein Pedersen , Birgitte Nissen , Patrick William Garibay , Kaisa Naelapaeae , Andreas Vegge
IPC分类号： A61K38/26 , A61K9/20 , A61K9/00 , A61K31/351 , A61K31/381 , A61K31/7048 , A61K31/382 , A61K31/7056
摘要： The invention relates to solid pharmaceutical compositions comprising a GLP-1 agonist, an SGLT2 inhibitor and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.
-
公开(公告)号：US20180000903A1
公开(公告)日：2018-01-04
申请号：US15543620
申请日：2016-01-28
申请人： Novo Nordisk A/S
CPC分类号： A61K38/26 , A61K9/0053 , A61K9/282 , A61K9/2846 , A61K9/5026 , A61K35/00 , A61K38/1709
摘要： The present invention relates to solid pharmaceutical compositions for oral administration comprising a GLP-1 agonist, an absorption enhancer which is a salt of medium-chain fatty acid, and an enteric coating as well as uses thereof.
-
4.发明公开公开(公告)号：US20240099981A1
公开(公告)日：2024-03-28
申请号：US18386839
申请日：2023-11-03
申请人： Novo Nordisk A/S
IPC分类号： A61K9/20 , A61K38/26 , A61P3/04 , A61P3/10 , C07K14/605
CPC分类号： A61K9/2013 , A61K38/26 , A61P3/04 , A61P3/10 , C07K14/605
摘要： The invention relates to pharmaceutical compositions comprising a peptide, such as a GLP-1 peptide and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.
-
公开(公告)号：US20220280611A1
公开(公告)日：2022-09-08
申请号：US17633047
申请日：2020-08-06
申请人： Novo Nordisk A/S
发明人： Andreas Vegge , Birgitte Schjellerup Wulff , Birgitte Nissen , Soeren Oestergaard , Betty Lomstein Pedersen
摘要： The present invention relates to a solid composition comprising a PYY compound and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.
-
6.发明申请公开(公告)号：US20200000728A1
公开(公告)日：2020-01-02
申请号：US16570723
申请日：2019-09-13
申请人： Novo Nordisk A/S
摘要： The invention relates to pharmaceutical compositions comprising a peptide, such as a GLP-1 peptide and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.
-
7.发明申请公开(公告)号：US20180263915A1
公开(公告)日：2018-09-20
申请号：US15546334
申请日：2016-01-28
申请人： Novo Nordisk A/S
CPC分类号： A61K9/284 , A61K9/0053 , A61K9/2013 , A61K9/2072 , A61K9/2866 , A61K9/2893 , A61K9/4808 , A61K9/5047 , A61K38/2278 , A61K38/26
摘要： The present invention relates to pharmaceutical compositions comprising a tablet core and an immediate release coating, wherein said tablet core comprises a GLP-1 peptide and an absorption enhancer, as well as uses thereof.
-
公开(公告)号：US20220323544A1
公开(公告)日：2022-10-13
申请号：US17628697
申请日：2020-08-07
申请人： Novo Nordisk A/S
摘要： The invention relates to pharmaceutical compositions comprising a PCSK9 inhibitor, such as an EGF(A) peptide, and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.
-
公开(公告)号：US20220062184A1
公开(公告)日：2022-03-03
申请号：US17531213
申请日：2021-11-19
申请人： Novo Nordisk A/S
摘要： The present invention relates to pharmaceutical compositions comprising a tablet core and an immediate release coating, wherein said tablet core comprises a GLP-1 peptide and an absorption enhancer, as well as uses thereof.
-
公开(公告)号：US10265384B2
公开(公告)日：2019-04-23
申请号：US15543620
申请日：2016-01-28
申请人： Novo Nordisk A/S
摘要： The present invention relates to solid pharmaceutical compositions for oral administration comprising a GLP-1 agonist, an absorption enhancer which is a salt of medium-chain fatty acid, and an enteric coating as well as uses thereof.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.029 秒)
